BiomX  logo
BiomX PHGE
$ 4.24 -2.97%

Annual report 2025
added 02-19-2026

report update icon

BiomX Financial Ratios 2011-2026 | PHGE

Annual Financial Ratios BiomX

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-0.2 -0.2 -0.7 -0.3 -1.1 -5.0 60.2 - - - - - - - -

EPS

22.2 25.4 0.5 0.9 1.4 1.3 3.7 7.6 - - - - - - -

EV (Enterprise Value)

4.2 M -13.2 M 4.6 M -22.1 M -23.9 M 128 M -50.5 M 40.6 K - - - - - - -

EBITDA per Share

-23.6 -61.1 -0.48 -0.83 -1.26 -1.2 -0.2 - - - - - - - -

EV/EBITDA

1.0 -4.2 -51.9 - - - - - - - -

PEG

-0.0 -0.0 - -0.08 0.59 - - - - - - - -

P/B

1.5 0.1 0.8 0.2 0.5 2.6 0.3 - - - - - - - -

P/CF

-0.3 -0.1 -0.9 -0.3 -1.4 -6.0 -102.2 - - - - - - - -

ROE %

2780.26 -73.41 -849.37 -134.59 -76.21 -52.35 0.49 - - - - - - - -

ROA %

-625.96 -41.00 -104.55 -62.19 -46.45 -42.76 0.49 - - - - - - - -

ROCE %

6957.38 -127.33 -182.98 -72.41 -52.97 -47.88 -0.57 - - - - - - - -

Current Ratio

- - - - - 8.5 2.0 - - - - - - - -

All numbers in USD currency

Quarterly Financial Ratios BiomX

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

0.29 0.19 0.33 - -0.31 -0.14 2.78 - 1.3 0.12 0.2 - 0.23 0.25 0.27 - 0.37 0.3 0.35 - 0.38 0.27 0.26 - 2.69 2.5 -0.25 - - -0.01 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

- - -0.33 - - - -1.05 - - - -0.19 - -0.21 -0.23 -0.24 - -0.3 -0.25 -0.33 - -0.31 -0.23 -0.24 - -2.16 -1.93 -0.25 -0.01 - -0.01 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

-124.74 -11.88 35.93 223.29 126.34 3.93 -52.78 -176.77 -202.29 -130.86 -113.31 -68.80 -87.57 -80.82 -73.06 -49.45 -64.82 -61.42 -57.12 -36.44 -41.48 -31.16 -24.83 -9.86 -9.84 -4.81 -0.13 -3.95 -3.97 -3.96 -4.17 - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

-51.59 -0.49 21.89 1.36 -22.56 -62.55 -84.61 -54.82 -67.88 -57.03 -54.30 -37.76 -50.03 -49.22 -48.31 -36.69 -49.25 -49.54 -46.46 -29.76 -34.39 -26.46 -21.74 -9.04 -9.02 -5.40 -1.28 -0.96 -0.99 0.01 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

-106.42 -87.85 -80.33 -55.69 -94.14 -110.40 -115.06 -78.87 -93.61 -69.91 -63.49 -42.08 -55.58 -54.35 -53.78 -41.47 -55.44 -55.91 -52.47 -33.53 -38.95 -30.39 -25.01 -10.87 -10.91 -5.50 -1.10 -4.54 -4.51 -4.50 -4.17 - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

- - - - - - - - - - - - - - - - - - - - - - - - 122.7 105.8 139.7 83.7 1.6 1730.5 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company BiomX , allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Alector Alector
ALEC
$ 2.08 -14.4 % $ 214 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Altimmune Altimmune
ALT
$ 4.2 -2.67 % $ 298 M usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
$ 20.24 -3.44 % $ 2.55 B usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.8 1.87 % $ 4.36 M chinaChina
Aprea Therapeutics Aprea Therapeutics
APRE
$ 0.88 -3.72 % $ 3.18 M usaUSA
Aptevo Therapeutics Aptevo Therapeutics
APVO
$ 7.2 -1.64 % $ 1.99 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.1 2.37 % $ 356 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 8.35 1.46 % $ 225 M israelIsrael
Ardelyx Ardelyx
ARDX
$ 6.37 -2.75 % $ 1.54 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
argenx SE argenx SE
ARGX
$ 756.71 -1.33 % $ 25 B niderlandNiderland
Armata Pharmaceuticals Armata Pharmaceuticals
ARMP
$ 10.91 1.58 % $ 394 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 25.33 -6.1 % $ 3.22 B usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Artelo Biosciences Artelo Biosciences
ARTL
$ 1.15 -3.36 % $ 2.32 M usaUSA
Arvinas Arvinas
ARVN
$ 12.97 -2.3 % $ 920 M usaUSA
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 61.74 -2.42 % $ 8.26 B usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 231.56 -0.83 % $ 5 B danmarkDanmark
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.39 -1.63 % $ 8.16 B australiaAustralia
Actinium Pharmaceuticals Actinium Pharmaceuticals
ATNM
$ 1.17 -0.85 % $ 35.2 M usaUSA
Atossa Therapeutics Atossa Therapeutics
ATOS
$ 4.39 -0.9 % $ 553 M usaUSA
Atara Biotherapeutics Atara Biotherapeutics
ATRA
$ 5.01 -7.47 % $ 37.5 M usaUSA
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
$ 14.14 -0.21 % $ 1.9 B canadaCanada
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.68 -1.75 % $ 429 M britainBritain
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
$ 4.69 0.21 % $ 395 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Anavex Life Sciences Corp. Anavex Life Sciences Corp.
AVXL
$ 4.54 2.44 % $ 387 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 570.5 5.18 % $ 43.2 B usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 162.28 -0.98 % $ 8.07 B usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.56 -0.58 % $ 16.1 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA